A 10-year-long study called the PanCancer Atlas is releasing a trove of genetic data in an effort to help doctors treat a wide variety of cancers more precisely.
The history: Over the past decade, 150 researchers from the US and around the world painstakingly analyzed DNA, RNA, and proteins from tumor samples of more than 11,000 patients with 33 different types of cancer.
The findings: From that data, scientists have identified about 300 genes that drive tumor growth. They also found that just over half the tumors samples analyzed carry genetic mutations that could be targeted by therapies that are already on the market. These findings and others appear in 29 different papers today in the journal Cell.
Why it matters: Researchers say the insights gleaned can be used to tailor more personalized treatments for cancer patients. “This analysis provides cancer researchers with unprecedented understanding of how, where, and why tumors arise in humans, enabling better-informed clinical trials and future treatments,” says Francis Collins, director of the US National Institutes of Health, which funded the project.
These scientists used CRISPR to put an alligator gene into catfish
The resulting fish appear to be more resistant to disease and could improve commercial production—should they ever be approved.
Next up for CRISPR: Gene editing for the masses?
Last year, Verve Therapeutics started the first human trial of a CRISPR treatment that could benefit most people—a signal that gene editing may be ready to go mainstream.
CRISPR for high cholesterol: 10 Breakthrough Technologies 2023
New forms of the gene-editing tool could enable treatments for common diseases.
An ALS patient set a record for communicating via a brain implant: 62 words per minute
Brain interfaces could let paralyzed people speak at almost normal speeds.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.